• Envoy Medical shareholders approved a reverse stock split authorization at a special meeting on October 12, 2026.
• The authorization covers one or more reverse stock splits of Class A Common Stock at ratios from 1-for-5 to 1-for-25.
• Implementation remains at the board’s discretion, with authority to execute the splits through December 31, 2026.
• Shareholders also approved a proposal allowing meeting adjournments to gather necessary votes or ensure a quorum; that authority was not used.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-110266), on October 16, 2026, and is solely responsible for the information contained therein.